Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.
Learn More

Introducing the Syn-One Test™ from CND Life Sciences

Offering physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy.

seal icon

CLIA-Certified Pathology Lab

test tube icon

Dedication to Science & Research

DNA icon

Patient-Focused Mission

microscope icon

Quality & Reliability at Our Core

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
July 8, 2021

New Research Supports Use of Skin Biopsies to Help Diagnose REM Sleep Behavior Disorder, a Prodrome of Parkinson’s Disease

Al-Qassabi and colleagues recently published a study in Movement Disorders that examined whether 3-mm skin…
Insights
June 22, 2021

CND Life Sciences Launches Its Power of Proof Campaign

CND Life Sciences continues to increase awareness and adoption of the skin-based Syn-One Test™ for…
Insights
May 27, 2021

Usefulness of the Syn-One Test™ in Evaluating Patients with Autonomic Symptoms

At the 2021 American Academy of Neurology meeting last month, Dr Alexandru Barboi and colleagues…
VIEW ALL INSIGHTS

Check out press releases, news alerts and coverage of CND happenings.

In the News
July 23, 2021

Epigenome-Editing Therapy Reduces Alpha-Synuclein Levels in Mice

Biopharmaceutical company Seelos Therapeutics in conjunction with researchers at Duke University School of Medicine announced…
In the News
July 19, 2021

FDA Narrows Indication for Biogen’s Aduhelm in Alzheimer’s Disease

Aducanumab, the first treatment for Alzheimer’s disease to be approved in nearly two decades, has…
In the News
June 16, 2021

Dr. Todd Levine Interviewed on Arizona ABC15 About New Alzheimer’s Treatment

Aducanumab, the first treatment for Alzheimer’s disease to be approved in nearly two decades, has…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Syn-One Test™ Kit

The Syn-One Test provides objective pathological evidence to aid in the diagnosis of a synucleinopathy. Simply collect three small punch skin biopsies from your patient, send them to our CLIA-certified lab, and CND Life Sciences will provide important visual insights to support a diagnosis. If you are a clinician, click below to order a Syn-One Test Biopsy Kit.

Order a Kit